Sofinnova Partners — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)
Co-investorsJeito CapitalSanofi VenturesVIVES PartnersApollo Health VenturesSixty Degree Capital
Ingenix builds an AI "Reasoning Engine" using an approach it calls Modality Fusion to integrate biological data across modalities and scales.
AI & Machine LearningBiotechDeep Tech
Adam Dancewicz(Founder)
Co-investorsInovo VCOTB VenturesIFC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.